Shenzhen Salubris Pharmaceuticals Co., Ltd.

Shenzhen Salubris Pharmaceuticals Co., Ltd. has seen a notable rise in its stock today, contrasting with a decline in the broader market. Over the past week and month, the company has demonstrated strong performance, although it faces challenges in long-term growth with modest annual net sales increases.

Shenzhen Salubris Pharmaceuticals Co., Ltd. has seen notable stock performance, gaining 5.65% on March 16, 2026, and achieving a 79.18% return over the past year. The company has a market capitalization of CNY 56,594 million and a price-to-earnings ratio of 109.00, with modest net sales growth of 6.94% annually.

Shenzhen Salubris Pharmaceuticals Co., Ltd. saw a notable increase in its stock price on March 10, 2026, outperforming the China Shanghai Composite. The company has shown strong performance over various time frames, although it faces challenges such as a high P/E ratio and modest dividend yield.

Shenzhen Salubris Pharmaceuticals Co., Ltd. saw a decline in stock performance today, contrasting with the broader market. Despite a strong annual growth rate, the company faces challenges such as a high price-to-earnings ratio and modest net sales growth, while navigating a complex market landscape.

Shenzhen Salubris Pharmaceuticals Co., Ltd. has shown strong performance recently, with notable increases over various time frames, significantly outpacing the Shanghai Composite. Despite a solid annual return, the company faces challenges in long-term growth, evidenced by modest net sales growth and a high price-to-earnings ratio.

Shenzhen Salubris Pharmaceuticals Co., Ltd. saw a significant stock decline today, contrasting with the broader market trend. Despite a strong annual performance, the company faces short-term challenges and fluctuating metrics, including a return on equity of 7.65% and a price-to-earnings ratio of 109.00, reflecting a complex market landscape.

Shenzhen Salubris Pharmaceuticals faced a challenging trading day on October 14, 2025, with a notable stock decline. Despite recent setbacks, the company has shown strong annual performance, significantly outperforming the broader market. It maintains a solid market capitalization and return on equity, though profit trends have declined slightly.

Shenzhen Salubris Pharmaceuticals Co., Ltd. faced a decline in stock value on October 13, 2025, with a notable drop over the past week. Despite recent challenges, the company has demonstrated strong long-term growth, achieving a significant increase over the past year and year-to-date, alongside solid financial metrics.

Shenzhen Salubris Pharmaceuticals Co., Ltd. has shown strong performance, with a significant increase on September 25, 2025, and a robust weekly gain. Over the past year, the company has achieved impressive growth, maintaining a high dividend yield and strong valuation metrics despite a recent decline in profits.